Considering AML‐MRC patients with intermediate cytogenetic prognosis (N = 35), the median survival was 178 days 95% CI (12‐344, N = 19) in ASXL1+, compared to 219 days CI 95% (145‐293, N = 16) in ASXL1−, P = .63 (Figure 3A). The gene discussed is ASXL1; the disease is acute myeloid leukemia.